Sequential method for determining the median effective dose (ED50) of remimazolam tosilate combined with sufentanil in patients with cirrhosis undergoing painless gastroscopy.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100041845

Enrollment

Unknown

Registered

2021-01-07

Start date

2021-02-23

Completion date

Unknown

Last updated

2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless Gastroscopy

Interventions

The remazolam tosylate group:The initial dose of 0.1mg/kg was followed by an increase or decrease of 0.025mg/kg of remimazolam tosylate depending on the last patient

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with cirrhosis due to various etiologies; 2. ASA class II-III; 3. Aged 18-65 years; 4. Child Pugh classification of liver function as grade A; 5. Indications for painless gastroscopy; 6. Agreed to be seen and treated with a sedated or anaesthetic gastroscope and to sign an informed consent form from the patient.

Exclusion criteria

Exclusion criteria: 1. Allergic to sedative, narcotic components. 2. Unable to take questionnaires due to various reasons.

Design outcomes

Primary

Measure	Time frame
Physical activity;	—

Secondary

Measure	Time frame
Choking reaction;	—

Countries

China

Contacts

Public ContactYinghao Cao

Beijing You'an Houspital Affiliated to Capital Medical University

cyhbi@sina.cn+86 13601091691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026